Guizhou Bailing Group Pharmaceutical Co., Ltd. (SHE:002424)
China · Delayed Price · Currency is CNY 4.150
+0.010 (0.24%)
Feb 4, 2026, 10:15 AM CST
SHE:002424 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 3,137 | 3,811 | 4,256 | 3,530 | 3,080 | 3,078 |
Other Revenue | 14.42 | 14.42 | 7.31 | 10.4 | 31.08 | 9.72 |
| 3,152 | 3,825 | 4,263 | 3,540 | 3,111 | 3,088 | |
Revenue Growth (YoY) | -25.47% | -10.27% | 20.42% | 13.79% | 0.75% | 8.33% |
Cost of Revenue | 1,502 | 1,660 | 1,953 | 1,438 | 1,271 | 1,355 |
Gross Profit | 1,650 | 2,166 | 2,310 | 2,103 | 1,840 | 1,733 |
Selling, General & Admin | 1,568 | 2,083 | 2,560 | 1,747 | 1,481 | 1,355 |
Research & Development | 35.87 | 23.1 | 42.04 | 22.4 | 30.43 | 37 |
Other Operating Expenses | 18.3 | 39.89 | 40.29 | 49.21 | 39.14 | 44.03 |
Operating Expenses | 1,592 | 2,146 | 2,713 | 1,879 | 1,617 | 1,537 |
Operating Income | 57.75 | 19.62 | -402.34 | 223.43 | 222.85 | 196.54 |
Interest Expense | -64.55 | -85.83 | -91.58 | -101.66 | -116.26 | -131.31 |
Interest & Investment Income | 19.36 | 24.93 | 6.54 | 31.18 | 3.74 | 71.58 |
Currency Exchange Gain (Loss) | - | - | 0 | 0 | 0.06 | -0.04 |
Other Non Operating Income (Expenses) | -5.68 | 34.69 | -16.83 | -22.87 | -33.05 | -0.64 |
EBT Excluding Unusual Items | 6.89 | -6.59 | -504.22 | 130.08 | 77.33 | 136.14 |
Gain (Loss) on Sale of Investments | -34.76 | -35.07 | -4.3 | 9.64 | 58.53 | 31.7 |
Gain (Loss) on Sale of Assets | -0.29 | -0.14 | 1.14 | -0.3 | -0.47 | 28.97 |
Asset Writedown | -38.62 | -0.12 | 0.15 | -0.09 | -0.92 | -0.49 |
Other Unusual Items | 108.83 | 108.83 | 14.17 | 19.72 | 7.16 | 12.44 |
Pretax Income | 42.05 | 66.91 | -493.07 | 159.06 | 141.63 | 208.77 |
Income Tax Expense | 33.98 | 30.14 | -80.61 | 22.81 | 32.1 | 55.04 |
Earnings From Continuing Operations | 8.07 | 36.77 | -412.46 | 136.25 | 109.53 | 153.73 |
Minority Interest in Earnings | -5.85 | -3.14 | -2.05 | 2.23 | 8.95 | -1.35 |
Net Income | 2.22 | 33.62 | -414.51 | 138.47 | 118.48 | 152.38 |
Net Income to Common | 2.22 | 33.62 | -414.51 | 138.47 | 118.48 | 152.38 |
Net Income Growth | - | - | - | 16.87% | -22.24% | -46.11% |
Shares Outstanding (Basic) | 1,644 | 1,681 | 1,382 | 1,385 | 1,481 | 1,385 |
Shares Outstanding (Diluted) | 1,644 | 1,681 | 1,382 | 1,385 | 1,481 | 1,385 |
Shares Change (YoY) | 14.88% | 21.67% | -0.22% | -6.50% | 6.92% | -2.02% |
EPS (Basic) | 0.00 | 0.02 | -0.30 | 0.10 | 0.08 | 0.11 |
EPS (Diluted) | 0.00 | 0.02 | -0.30 | 0.10 | 0.08 | 0.11 |
EPS Growth | - | - | - | 25.00% | -27.27% | -45.00% |
Free Cash Flow | 597.14 | -33 | 21.65 | 433.7 | -100.81 | 454.39 |
Free Cash Flow Per Share | 0.36 | -0.02 | 0.02 | 0.31 | -0.07 | 0.33 |
Gross Margin | 52.35% | 56.61% | 54.19% | 59.39% | 59.13% | 56.13% |
Operating Margin | 1.83% | 0.51% | -9.44% | 6.31% | 7.16% | 6.37% |
Profit Margin | 0.07% | 0.88% | -9.72% | 3.91% | 3.81% | 4.93% |
Free Cash Flow Margin | 18.95% | -0.86% | 0.51% | 12.25% | -3.24% | 14.71% |
EBITDA | 161.92 | 124.07 | -297.53 | 326.77 | 318.05 | 293.03 |
EBITDA Margin | 5.14% | 3.24% | -6.98% | 9.23% | 10.22% | 9.49% |
D&A For EBITDA | 104.17 | 104.45 | 104.82 | 103.35 | 95.2 | 96.48 |
EBIT | 57.75 | 19.62 | -402.34 | 223.43 | 222.85 | 196.54 |
EBIT Margin | 1.83% | 0.51% | -9.44% | 6.31% | 7.16% | 6.37% |
Effective Tax Rate | 80.81% | 45.05% | - | 14.34% | 22.66% | 26.37% |
Revenue as Reported | 3,152 | 3,825 | 4,263 | 3,540 | 3,111 | 3,088 |
Advertising Expenses | - | - | - | - | - | 92.39 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.